PHARMANEST

PharmaNest, a leader in high-resolution single-fiber digital pathology and AI, will present five communications at Digestive Disease Week (DDW) 2026, showcasing its advanced technologies for the study of fibrosis and tissue remodeling in preclinical and clinical settings across inflammatory bowel disease (IBD) and eosinophilic esophagitis (EoE).

PharmaNest Inc. announced today a multi-institutional research collaboration with Virginia Commonwealth University (VCU) and the National Institutes of Health (NIH) to confirm the prognostic performance of artificial intelligence (AI) powered digital pathology biomarkers in metabolic dysfunction-associated steatotic liver disease (MASLD) in a retrospective cohort of 1,765 patients with MASH (NASH CRN DB2 Cohort)

FibroMAP combines the power of high-resolution, single-fiber, and spatially resolved datasets generated by PharmaNest's digital pathology and image analysis platform (FibroNest) with advanced clustering techniques such as Uniform Manifold Approximation and Projection (UMAP) to interpret complex, high-dimensional data. FibroMAP is poised to revolutionize the study of fibrosis histology in the same way that single-cell analysis transformed biology.

PharmaNest, a leader in high-resolution, single-fiber quantitative Digital Pathology and Artificial Intelligence, showcases the performance of its FibroNest Ph-FCS digital biomarker for quantifying fibrosis severity and its clinical utility in Phase 2 and Phase 3 studies for patients with Metabolic Associated Steatohepatitis (MASH).

PharmaNest, a leader in high resolution quantitative Digital Pathology and Artificial Intelligence, announces today the launch new quantitative tissue panels to properly quantify tissue injury and inflammation in the context of multiple fibrotic conditions, from discovery models to clinical development. Such spatially resolved datasets can be fused with other spatially resolved biology methods.

PharmaNest, a leader in high resolution, single-fiber, quantitative Digital Pathology and Artificial Intelligence, showcases the utility and performance of its FibroNest Ph-FCS continuous fibrosis biomarker for the quantification of the severity of fibrosis and prognostics of liver related clinical events in NASH.

PharmaNest, an emerging leader in quantitative Digital Pathology and Artificial Intelligence, showcases the utility and performance of its FibroNest continuous scores for the quantification of the treatment effects of NASH therapies at the 2022 Liver Meeting® | AASLD conference

The QUID-NASH Research Consortium (Paris, France) and PharmaNest, Inc. (Princeton, USA) enter a strategic partnership to use artificial intelligence (AI) powered tool for the diagnosis and staging of NASH (non-Alcoholic Steatohepatitis) in patients with type 2 diabetes (T2D).

PharmaNest, an emerging leader in quantitative Digital Pathology and Artificial Intelligence, showcases the utility and performance of its FibroNest continuous score for the quantification of the severity of fibrosis and treatment effects of NASH therapies at the 2022 International Liver Conference.

New digital pathology, quantitative image analysis and quantitative AI method for liver tissues is presented for the continuous assessment of the histological phenotype(s) of fibrosis, including severity and regression of fibrosis in Human in-vitro 3D NASH Spheroid models, NASH rodent models, Clinical Phase2b NASH Studies at the Liver Meeting Digital Experience™ 2021

Introduction of key technology to accelerate NASH drug discovery by combining 3D disease models and automated AI-based fibrosis quantification

New digital image analysis data of stained tissues and biopsies with FibroNest is presented for the continuous assessment of the severity and regression of Fibrosis in human in-vitro 3D NASH Spheroid models and for the automated classification of post-transplant patients in F4 Fibrosis Stage with and without Hepatocellular carcinoma (HCC) at the Liver Meeting Digital Experience 2020

New digital image analysis data of stained tissues and biopsies with FibroNest is presented for the continuous assessment of the severity and progression of fibrosis in NASH in pre-clinical tissues and adult NASH biopsies at the Digital International Liver CongressTM 2020

New image analysis data of tissues with FibroNest™ is presented for the continuous assessment of the severity and progression of fibrosis in Kidney and Lung preclinical models at the Fibrosis and Tissue Repair 2020 Keystone Symposium. FibroNest image analysis tool provides the most advanced cloud-based phenotypic image analysis and translational platform for the automated quantification of fibrosis across multiple fibrotic conditions and organs for drug discovery and drug development projects.

New image analysis data of biopsies with FibroNest is presented for the continuous assessment of the severity and progression of fibrosis in NASH in both adult and pediatric cohorts at the Liver Meeting® 2019.

FibroNest cloud-based image analysis tool provides the most advanced phenotypic image analysis and translational platform for the automated quantification of fibrosis and steatosis for NASH and for other fibrotic conditions in drug discovery and drug development projects.

Accelence is pleased to announce a partnership with PharmaNest, a contract operations organization marketing breakthrough International IND-Enabling Technologies and Services for the US Markets

Accelence is pleased to announce a partnership with PharmaNest, a contract operations organization who commercializes breakthrough International IND-Enabling Technologies and Services for the US Markets.

CYTOO SA, a company that specializes in cell-based assays, is pleased to introduce 2D+: A New Dimension in Cell Culture.

CYTOO Inc,the US subsidiary of CYTOO SA, is pleased to announce a partnership with PharmaNest, a contract operations organization who commercializes breakthrough International IND-Enabling Technologies and Services for the US Markets.